Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07177339 · ClinicalTrials.gov registry record · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,196
- Enrollment target
- 6
- Study locations
NCT07177339: Recruiting Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
NCT07177339 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 1,196 participants, above the 1,028-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (16% higher). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07177339, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,196 participants
- Enrollment target
- 6
- Study locations
Study Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.
Primary Outcome
Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (that is greater than or equal to \[\>=\] 24 hours) or result in death. The frequency of moderate/ severe exacerbations expressed as an annualized rate of moderate or severe exacerbations will be reported.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Depemokimab
Study Locations (6)
Other
- GSK Investigational Site - Chengdu
- GSK Investigational Site - Guilin
- GSK Investigational Site - Jiangmen
- GSK Investigational Site - Nanchang
- GSK Investigational Site - Taizhou
Florida
- GSK Investigational Site - Doral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,196 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2029-12-14 |
| Phase | Phase 3 |
What NCT07177339 shows while recruiting
NCT07177339 is an interventional study that assigns participants to a tested intervention. Its 1,196 participants enrollment target places it among the larger protocols in the corpus, above the 1,028-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (16% higher).
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07177339 lists 6 locations in 2 states (Other, Florida).
Frequently Asked Questions
What is clinical trial NCT07177339 about?
NCT07177339 is a clinical study titled "eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation". Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with t...
What is the current status of trial NCT07177339?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,196 participants. The study started on 2025-10-20. Estimated completion is 2029-12-14.
What conditions does trial NCT07177339 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT07177339?
The interventions under investigation include: Placebo (DRUG), Depemokimab (DRUG).
Who is sponsoring clinical trial NCT07177339?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07177339 being conducted?
This trial has 6 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07177339's enrollment target sits among peer trials
1,196 11th of 74 higher than 64 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
-
Tiotropium / Respimat One-Year Study
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI